58 results about "Trichomonas vaginalis" patented technology

A vaginal treatment composition that employs a therapeutic agent to inhibit and/or treat vaginal infection is provided. The therapeutic agent is capable of inhibiting and/or killing Gardnerella (e.g., Gardnerella vaginalis), Candida (e.g., Candida albicans), and/or Trichomonas (e.g., Trichomonas vaginalis) pathogens. Desirably, such antimicrobial efficacy is achieved without substantially inhibiting the growth of Lactobacillus acidophilus. For instance, sugars and/or sugar alcohols may be employed in the present invention as a therapeutic agent for inhibiting and/or treating vaginal infection. In one particular embodiment, D-xylitol is used as the therapeutic agent.

A tablet for insertion into a vagina including 0.01 to 500 mg of a vaginal medication, such as a microbicide, such as cellulose acetate 1,2-benzenedicarboxylate (CAP); 100 to 500 mg of mannitol powder; 50 to 300 mg of inert microcrystalline cellulose; 10 to 80 mg of hydroxypropyl methylcellulose; 50 to 250 mg of glycerol and optionally 2 to 4 mg of at least one preservative which protects against microbicidal contamination and discourages the growth of yeast in the vagina. The tablet which includes CAP as the vaginal medication is vaginally administered before coitus in methods for preventing the sexual transmission of HIV-1, HIV-2, herpesvirus, or an infection caused by Neisseria gonorrhoeae, Chlamydia trachomatis, Trichomonas vaginalis, Haemophilus ducreyi or Treponema pallidum. The tablet which includes CAP as the vaginal medication is vaginally administered to prevent or treat bacterial vaginosis.

The invention relates to a gynaecologic lotion relative to female pudendum, which is prepared by extracting glabrous greenbrier rhizome, radix stemonae, cave flower, common cnidium fruit, lightyellow sophora root, phellodendron, European vebena, densefruit pittany root-bark, broom cypress fruit, golden larch bark, shrubalthea bark, Chinese gall, pariphyllin, pericarpium zanthoxyli, indigo naturalis, borneol and white vitriol, and has the effects of reducing fever, detoxifying, eliminating dampness, diminishing inflammation, depriving body fluids, disinfesting insect, stopping leucorrhea, relieving itching, retracting, etc. The lotion can effectively kill pathogenic bacteria, such as trichomonas vaginalis, mucedine, gonococcus, chlamydia, etc., and has the effects of diminishing inflammation, eliminating dampness, stopping leucorrhea and relieving itching. The lotion has good curative effects on various colpitis, multi-colorea leucorrhea, pruritus vulvue, hysteroptosis, prolapse of uterus, vaginal looseness, etc.

Disclosed are a DNA chip and a kit capable of quickly and accurately detecting or genotyping the highly prevalent and important eleven microbes causing sexually transmitted diseases (STD) Neisseria gonorrhoeae, Chlamydia trachomatis, Ureaplasma urealyticum, Mycoplasma genitalium, Mycoplasma hominis, syphilis-causing treponema, pallidum, chancroid-causing Haemophilus ducreyi, genital herpes-causing herpes simplex virus 1 and 2, human papillomavirus (HPV) and Trichomonas vaginalis and three related organisms Candida albicans, Gardnerella vaginalis and coliform bacteria and analyzing antibiotic resistance against tetracycline and lactam antibiotics, and a method for detecting or genotyping using the same. According to the present invention, the presence, genotype and antibiotic resistance of the fourteen organisms can be analyzed quickly and accurately from a DNA sample. With excellent sensitivity, specificity, reproducibility and accuracy of the 14 STD-causing and related microorganisms may be automatically identified quickly and accurately from multiple samples, and selection of antibiotics may be aided.

A method and kit for detecting Trichomonas vaginalis infection in a human subject are disclosed. In the method, a body-fluid sample such as a vaginal swab sample or urine is obtained from the subject and contacted with an antibody specific against a Trichomonas adhesin peptide, forming an antibody-adhesin peptide complex if the subject is infected with Trichomonas. The presence or absence of the complex establishes, with a reliability of at least 80%, in the case of a vaginal swab sample, and with a reliability of at least 40% in the case of a urine sample, the presence or absence, respectively, of Trichomonas infection in the subject. A preferred test kit employs a dry-strip, sandwich assay, format.

Proguanil has been found to have rapid and effective killing activity against a variety of disease-causing micro organisms. For example, when applied topically, proguanil is particularly effective against Propionibacterium acnes, a bacteria that causes acne; Corynebacterium minutissimum, a bacteria that causes erythrasma, Gardnerella vaginalis, a bacteria that causes vaginosis; Trichomonas vaginalis, a protozoan that causes trichomoniasis and C. albicans, a fungus (a form of yeast).

The invention discloses a nano iodine-chitosan cervical disease treating membrane agent and a preparation method of the membrane. The treating membrane is prepared by adding plasticizer and adsorbent to chitosan, povidone iodine, dialkyl quaternary ammonium salt and chlorhexidine acetate used as main effective ingredients. The treating membrane disclosed by the invention has killing activity to multiple pathogenic microorganisms, has no irrigation to mucosa, can relieve itching, arrest bleeding and promote the growth of epidermic tissues, can be used for treating colpitis, trichomonas vaginalis, cervicitis, cervical erosion and other gynecological diseases, has better repair action on vaginal and cervical injury, and can effectively prevent the propagation of venereal diseases such as gonorrhoea, syphilis, AIDS (acquired immunodeficiency syndrome) and the like.

The use of levo-ornidazole in the preparation of anti-parasitic infection drug is provided. It is demonstrated that levo-ornidazole is superior to dextro-ornidazole and racemic ornidazole in the therapeutic action against parasitization (especially trichomonas vaginalis infection and cecal amoeba infection), and thus it is more practicable to formulate L-ornidazole as anti-parasitic infection drugs, and particularly as drug preparations which are suitable for clinical uses, including oral preparation, intravenous preparation and vaginal preparation.

The present invention provides an application of levomorpholinonidazol [R-(-)-1-(2-methyl-5nitroimidazole-1-group)-morpholinylpropane-2-alcohol] or its medicinal salt in preparation of medicine for resisting amoebic infection and resisting vaginal trichomonad infection.

Oligonucleotides useful for determining the presence of Trichomonas vaginalis in a test sample.

The invention relates to the technical field of detection of pathogenic microorganisms, in particular to a primer and probe set and kit for multi-detection of gardnerella vaginalis, canidia albicans and trichomonas vaginalis and a detection method. The kit comprises specific primer pairs and Taqman fluorescence probes for conservative areas of GD/CA/TV, and the kit can accurately detect samples infected with GD/CA/TV through real-time fluorescence quantification PCR and is high in sensitivity, good in specificity, high in repeatability and convenient and quick to use.

A freeze-dried powder injection of metronidazole for treating anaerobe infection, Trichomonas vaginalis and amebiasis is prepared from metronidazole through depositing in water, cold storage, ultrafiltration, further preparing in dark condition and N2 atmosphere, pouring in containers, freeze drying and sealing.

A process for inhibiting a mammalian cancerous cell or virally infected cell includes providing a Trichomonas vaginalis purine nucleoside phosphorylase enzyme or a tail mutant purine nucleoside phosphorylase enzyme in proximity to the mammalian cancerous cell or the virally infected cell and exposing the enzyme to a purine nucleoside phosphorylase enzyme cleavable substrate to yield a cytotoxic purine analog. The process includes introducing to the cell a vector containing the phosphorylase enzyme, or a DNA sequence coding for the same and delivering to the cell an effective amount of the substrate such as 9-(β-D-arabinofuranosyl)-2-fluoroadenine (F-araA).

The present invention is Chinese medicine composition for treating women's diseases and its production process. The externally applied medicine is used in treating women's inflammation caused by trichomonas vaginalis, fungus and bacteria. The Chinese medicine composition contains honeysuckle, sessile stemona root, phellodendron bark and other plant medicine materials, borax and borneol.

A novel veterinary anti-inflammation agent and a preparation method of the same. The multifunctional veterinary anti-inflammation agent is prepared by extracting effective components from following traditional Chinese medicine raw materials including: pseudo-ginseng, gentiana scabra, radix stellariae, herba houttuyniae, rhubarb, sophora flavescens, dandelion, cowherb seeds and liquidambar formosana and the like, by means of a bio-fermentation engineering technology and a bio-chemical engineering technology according to a special process and a special formula. The anti-inflammation agent can safely, high-effectively, quickly and synchronously kill six categories of pathogenic microorganisms including bacteria, fungus, viruses, mycoplasma, chlamydia and protozoons (including staphylococcus aureus, escherichia coli, candida albicans, herpes virus vaginalis, mycoplasma urealytium, chlamydia vaginalis, trichomonas vaginalis and the like). The anti-bacterial range of the anti-inflammation agent greatly exceeds a limit that conventional antibiotics only can kill and inhibit bacteria. The anti-inflammation agent is free of generation of polluting substances not only in production but also in use, is low in production cost, is good in effects and is free of toxic and side effects, can be used for replacing the antibiotics to eliminate damage on human body and livestock due to "antibiotic-milk" and "antibiotic-meat", can effectively prevent and treat inflammation ingenital tract and mammary gland of cattle, horses, sheep, pigs, dogs, wild animals and pets, and is very wide in market prospect.

The invention provides a kit for quantitatively detecting trichomonas vaginalis by a chemiluminiscence method. In use, a trichomonas vaginalis antigen in a sample reacts with a reagent in the kit to generate a neutral avidin microsphere-capture antibody-antigen-detection antibody-acridinium ester compound; washing is carried out to remove substances which do not participate in the reaction; and when acridinium ester is in an alkaline H2O2 solution, molecules are attacked by hydrogen peroxide ions, unstable dioxane is generated, the dioxane is decomposed into CO2 and N-methyl acridone in an electron excited state, photons are emitted when acridinium ester returns to a ground state, and a light-emitting signal measuring instrument is used for measuring the light quantum yield for measurement. Meanwhile, a quantitative standard curve is fitted through a calibrator, and the concentration of trichomonas vaginalis is calculated by substituting the light signal measurement result of the sample into the quantitative standard curve. The kit provided by the invention is used for quantitative detection of trichomonas vaginalis, the sensitivity is high, the specificity is good, and the concentration of trichomonas vaginalis in the sample can be accurately detected.

The present invention is directed to the discovery of single nucleotide polymorphisms (SNPs) in the presence of metronidazole-resistant Trichomonas vaginalis. The presence of G76C, C213G, or C318A (SNP) in tvntr 4 or the presence of A238T, G427C, or T476C (SNP) in tvntr6 provides a reliable biomarker for the presence of metronidazole-resistant Trichomonas vaginalis. The present invention further provides reagents used for detecting the SNPs to screen subjects for metronidazole resistance in Trichomonas vaginalis.